首页> 美国卫生研究院文献>American Journal of Physiology - Regulatory Integrative and Comparative Physiology >Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats
【2h】

Intravesical TRPV4 blockade reduces repeated variate stress-induced bladder dysfunction by increasing bladder capacity and decreasing voiding frequency in male rats

机译:膀胱内TRPV4阻断可通过增加雄性大鼠的膀胱容量和减少排尿频率来减少反复的压力应激性膀胱功能障碍

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Individuals with functional lower urinary tract disorders including interstitial cystitis (IC)/bladder pain syndrome (BPS) and overactive bladder (OAB) often report symptom (e.g., urinary frequency) worsening due to stress. One member of the transient receptor potential ion channel vanilloid family, TRPV4, has recently been implicated in urinary bladder dysfunction disorders including OAB and IC/BPS. These studies address the role of TRPV4 in stress-induced bladder dysfunction using an animal model of stress in male rats. To induce stress, rats were exposed to 7 days of repeated variate stress (RVS). Quantitative PCR data demonstrated significant (P ≤ 0.01) increases in TRPV4 transcript levels in urothelium but not detrusor smooth muscle. Western blot analyses of split urinary bladders (i.e., urothelium and detrusor) showed significant (P ≤ 0.01) increases in TRPV4 protein expression levels in urothelial tissues but not detrusor smooth muscle. We previously showed that RVS produces bladder dysfunction characterized by decreased bladder capacity and increased voiding frequency. The functional role of TRPV4 in RVS-induced bladder dysfunction was evaluated using continuous, open outlet intravesical infusion of saline in conjunction with administration of a TRPV4 agonist, GSK1016790A (3 μM), a TRPV4 antagonist, HC067047 (1 μM), or vehicle (0.1% DMSO in saline) in control and RVS-treated rats. Bladder capacity, void volume, and intercontraction interval significantly decreased following intravesical instillation of GSK1016790A in control rats and significantly (P ≤ 0.01) increased following administration of HC067047 in RVS-treated rats. These results demonstrate increased TRPV4 expression in the urothelium following RVS and that TRPV4 blockade ameliorates RVS-induced bladder dysfunction consistent with the role of TRPV4 as a promising target for bladder function disorders.
机译:具有功能性下尿路疾病的个体包括间质性膀胱炎(IC)/膀胱疼痛综合征(BPS)和膀胱过度活动症(OAB),通常会因压力而导致症状恶化(例如尿频)。 TRPV4是瞬时受体电位离子通道香草素家族的成员之一,最近与膀胱功能障碍疾病有关,包括OAB和IC / BPS。这些研究使用雄性大鼠的应激动物模型解决了TRPV4在应激诱导的膀胱功能障碍中的作用。为了诱发压力,使大鼠暴露于7天的反复变化压力(RVS)中。定量PCR数据显示,尿路上皮中TRPV4转录水平显着增加(P≤0.01),但逼尿肌平滑肌无明显增加。对分裂的膀胱(即尿路上皮和逼尿肌)进行的蛋白质印迹分析表明,尿路上皮组织中TRPV4蛋白表达水平显着增加(P≤0.01),而逼尿肌平滑肌则没有。我们以前表明,RVS会导致膀胱功能障碍,其特征是膀胱容量减少和排尿频率增加。使用连续,开放式膀胱腔内注入盐水和TRPV4激动剂,GSK1016790A(3μM),TRPV4拮抗剂,HC067047(1μM)或赋形剂(对照组和RVS治疗组大鼠的生理盐水中加入0.1%DMSO。膀胱内滴注GSK1016790A后,对照组大鼠的膀胱容量,空隙体积和收缩间隔明显降低,而在接受RV067治疗的大鼠中,HC067047给药后膀胱容量,空隙体积和收缩间隔明显延长(P≤0.01)。这些结果表明,RVS后尿路上皮中TRPV4表达增加,并且TRPV4阻滞改善了RVS引起的膀胱功能障碍,与TRPV4作为膀胱功能障碍的有希望的靶标的作用一致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号